Gara Jalqabaatti › Luukemiya Mayiloomonositikii Keessummaa
Qorannoo klinikaalii Luukemiya Mayiloomonositikii Keessummaa Ameerikaa Keessatti hirmaatuu
Qorannoo 42 Luukemiya Mayiloomonositikii Keessummaa f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Houston, TXQorannoo 16
- Seattle, WAQorannoo 10
- Boston, MAQorannoo 7
- Mountain View, CAQorannoo 6
- Baldwin Park, CAQorannoo 6
- Rochester, MNQorannoo 6
- New York City, NYQorannoo 6
- Durham, NCQorannoo 5
- Miami, FLQorannoo 4
- Tampa, FLQorannoo 4
- Birmingham, ALQorannoo 4
- Columbus, OHQorannoo 4
- Atlanta, GAQorannoo 4
- Nashville, TNQorannoo 3
- Portland, ORQorannoo 3
- Los Angeles, CAQorannoo 3
- Charleston, SCQorannoo 3
Naannoon
- AlabamaQorannoo 4
- CaliforniaQorannoo 12
- FloridaQorannoo 8
- GeorgiaQorannoo 4
- MarylandQorannoo 3
- MassachusettsQorannoo 7
- MinnesotaQorannoo 7
- New YorkQorannoo 8
- North CarolinaQorannoo 5
- OhioQorannoo 5
- OregonQorannoo 3
- PennsylvaniaQorannoo 4
- South CarolinaQorannoo 3
- TennesseeQorannoo 3
- TexasQorannoo 18
- WashingtonQorannoo 10
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06904066Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT06523556Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 12-Hag-2026 · NCT07143669Pacritinib in CMML
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06159491Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Namoota walitti qabaa jiraSadarkaa 2/3Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 hanga 80 · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT05092451Personalized NK Cell Therapy in CBT
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 15 hanga 80 · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT02727803Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Ado-2026 · NCT07046078Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ado-2026 · NCT07128381Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 65 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT01137825Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT06815003211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT03670966211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT03128034Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT05549661Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 03-Wax-2026 · NCT03964506Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
6 Months · Saalaa hunda · Haaromfame 29-Cam-2026 · NCT04195633Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.